Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2017

NSCLC has one of the most dynamic drug development pipelines in oncology, including multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust growth throughout the 2016-2026 forecast period. The biggest driver of market sales growth will be the continued uptake and anticipated label expansions of immune checkpoint inhibitors. Merck & ;s Keytruda became the first immune checkpoint inhibitor to receive approval for first-line NSCLC and is anticipated to generate significant sales in this setting. EGFR and ALK inhibitor drug classes will also contribute to market growth following the first-line label expansions of Tagrisso and Alecensa, respectively. Several new therapies will gain approvals within the forecast period, from four different drug classes, resulting in increased therapy options and a highly competitive market. 
Questions Answered 

• How large are the drug-treatable NSCLC populations and how will the drug-treatment rates change over time? 
• What is the current state of treatment in NSCLC ? What are interviewed experts’ insights on current treatment options?  What clinical needs remain unfulfilled? 
• How will different immune checkpoint inhibitor regimens compete in the first-line metastatic NSCLC setting? What will patient share dynamics look like in high PD-L1  ( TPS  ≥50%) and negative/low- PD-L1 patient segments? 
• What will be the therapy options for EGFR – and ALK -positive patients following progression on first-line Tagrisso and Alecensa, respectively? 
• What pipeline products are most promising, and what sales/uptake could they secure in NSCLC ? What therapies of note are progressing in earlier phases? 
• What are the drivers and constraints in the NSCLC market, and how will the market evolve over the forecast period? 

Product Description 
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.